|
WO1999010349A1
(en)
|
1997-08-22 |
1999-03-04 |
Zeneca Limited |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
|
JP2002527436A
(en)
*
|
1998-10-08 |
2002-08-27 |
アストラゼネカ アクチボラグ |
Quinazoline derivatives
|
|
GB2345486A
(en)
*
|
1999-01-11 |
2000-07-12 |
Glaxo Group Ltd |
Heteroaromatic protein tyrosine kinase inhibitors
|
|
IL144144A0
(en)
|
1999-01-13 |
2002-05-23 |
Bayer Ag |
Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
CZ305827B6
(en)
|
1999-02-10 |
2016-03-30 |
Astrazeneca Ab |
Indole derivatives
|
|
ATE377597T1
(en)
*
|
1999-07-09 |
2007-11-15 |
Glaxo Group Ltd |
ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS
|
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
|
GB9922171D0
(en)
|
1999-09-21 |
1999-11-17 |
Zeneca Ltd |
Chemical compounds
|
|
PL354323A1
(en)
|
1999-09-21 |
2004-01-12 |
Astrazeneca Ab |
Quinazoline derivatives and their use as pharmaceuticals
|
|
UA74803C2
(en)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
|
|
AU2001228638A1
(en)
|
2000-01-28 |
2001-08-07 |
Astrazeneca Ab |
Chemical compounds
|
|
GEP20063831B
(en)
|
2000-06-22 |
2006-05-25 |
Pfizer Prod Inc |
Substituted bicyclic derivatives for treatment of abnormal cell growth
|
|
WO2002000649A1
(en)
|
2000-06-28 |
2002-01-03 |
Astrazeneca Ab |
Substituted quinazoline derivatives and their use as inhibitors
|
|
AU2001276536B2
(en)
|
2000-08-09 |
2007-01-04 |
Astrazeneca Ab |
Quinoline derivatives having vegf inhibiting activity
|
|
AU2001293817A1
(en)
|
2000-09-20 |
2002-04-02 |
Merck Patent Gmbh |
4-amino-quinazolines
|
|
RU2264389C3
(en)
|
2000-10-20 |
2018-06-01 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
NITROGEN-CONTAINING AROMATIC DERIVATIVES, THEIR APPLICATION, MEDICINE ON THEIR BASIS AND METHOD OF TREATMENT
|
|
ES2344592T3
(en)
|
2001-01-05 |
2010-09-01 |
Pfizer Inc. |
ANTIBODIES AGAINST THE RECEIVER OF THE SIMILAR GROWTH FACTOR TO INSULIN I.
|
|
PT1370553E
(en)
*
|
2001-03-23 |
2006-09-29 |
Bayer Corp |
RHOQUINASE INHIBITORS
|
|
CA2441501C
(en)
*
|
2001-03-23 |
2010-09-14 |
Bayer Corporation |
Rho-kinase inhibitors
|
|
ATE330956T1
(en)
|
2001-04-13 |
2006-07-15 |
Pfizer Prod Inc |
BIZYCLIC SUBSTITUTED 4-AMINOPYRIDOPYRIMIDINE DERIVATIVES
|
|
AU2002345792A1
(en)
|
2001-06-21 |
2003-01-08 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
|
US7829566B2
(en)
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
|
AR039067A1
(en)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
ANTIBODIES FOR CD40
|
|
ES2305435T3
(en)
|
2002-01-10 |
2008-11-01 |
Bayer Healthcare Ag |
INHIBITORS OF RHO-QUINASA.
|
|
MXPA04007191A
(en)
|
2002-01-23 |
2005-03-31 |
Bayer Pharmaceuticals Corp |
Pyrimidine derivatives as rho-kinase inhibitors.
|
|
ATE381557T1
(en)
|
2002-01-23 |
2008-01-15 |
Bayer Pharmaceuticals Corp |
RHO KINASE INHIBITORS
|
|
RU2362775C1
(en)
|
2002-02-01 |
2009-07-27 |
Астразенека Аб |
Quinazoline compounds
|
|
EP1478358B1
(en)
|
2002-02-11 |
2013-07-03 |
Bayer HealthCare LLC |
Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
|
BR0317548A
(en)
|
2002-12-19 |
2005-11-22 |
Pfizer |
Indazole compounds and pharmaceutical compositions for protein kinase inhibition and methods for their use
|
|
NZ541861A
(en)
|
2003-02-26 |
2009-05-31 |
Sugen Inc |
Aminoheteroaryl compounds as protein kinase inhibitors
|
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US8796250B2
(en)
|
2003-05-20 |
2014-08-05 |
Bayer Healthcare Llc |
Diaryl ureas for diseases mediated by PDGFR
|
|
HN2004000285A
(en)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTIBODIES DIRECTED TO c-MET
|
|
JP2007504122A
(en)
|
2003-08-29 |
2007-03-01 |
ファイザー・インク |
Thienopyridine-phenylacetamide and its derivatives useful as novel anti-angiogenic agents
|
|
AR045563A1
(en)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
ANTIBODIES DIRECTED TO M-CSF
|
|
EP1664030A1
(en)
*
|
2003-09-16 |
2006-06-07 |
AstraZeneca AB |
Quinazoline derivatives
|
|
DK1667991T3
(en)
|
2003-09-16 |
2008-08-18 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
CN100450998C
(en)
|
2003-11-11 |
2009-01-14 |
卫材R&D管理有限公司 |
Process for the preparation of urea derivatives
|
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
TW200536851A
(en)
|
2004-01-23 |
2005-11-16 |
Amgen Inc |
Compounds and methods of use
|
|
EP1711495A2
(en)
|
2004-01-23 |
2006-10-18 |
Amgen Inc. |
Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
|
|
US7632840B2
(en)
|
2004-02-03 |
2009-12-15 |
Astrazeneca Ab |
Quinazoline compounds for the treatment of hyperproliferative disorders
|
|
AU2005239878B9
(en)
|
2004-05-06 |
2010-01-07 |
Warner-Lambert Company Llc |
4-phenylamino-quinazolin-6-yl-amides
|
|
RU2342159C2
(en)
|
2004-07-16 |
2008-12-27 |
Пфайзер Продактс Инк. |
Combined therapy for non-hematologic malignant tumours using anti-igf-1r antibody
|
|
CN101023064B
(en)
|
2004-08-26 |
2011-02-16 |
辉瑞大药厂 |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
|
CN101001629B
(en)
|
2004-09-17 |
2010-05-05 |
卫材R&D管理有限公司 |
Pharmaceutical composition
|
|
JP2008521900A
(en)
|
2004-11-30 |
2008-06-26 |
アムジエン・インコーポレーテツド |
Quinolines and quinazoline analogues and their use as medicaments for the treatment of cancer
|
|
ATE501148T1
(en)
|
2004-12-14 |
2011-03-15 |
Astrazeneca Ab |
PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTI-TUMOR AGENTS
|
|
RU2413735C2
(en)
|
2005-03-31 |
2011-03-10 |
Эдженсис, Инк. |
Antibodies and related molecules binding with proteins 161p2f10b
|
|
KR100990027B1
(en)
|
2005-04-26 |
2010-10-26 |
화이자 인코포레이티드 |
P-cadherin antibody
|
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Substituted Amid derivatives & methods of use
|
|
JP4989476B2
(en)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Methods for assaying the effects of angiogenesis inhibitors
|
|
TWI370137B
(en)
|
2005-09-07 |
2012-08-11 |
Amgen Fremont Inc |
Human monoclonal antibodies to activin receptor-like kinase-1
|
|
WO2007035744A1
(en)
|
2005-09-20 |
2007-03-29 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
EP1928861B1
(en)
|
2005-09-20 |
2010-11-17 |
AstraZeneca AB |
4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
CN101003514A
(en)
*
|
2006-01-20 |
2007-07-25 |
上海艾力斯医药科技有限公司 |
Derivative of quinazoline, preparation method and usage
|
|
BRPI0711358A2
(en)
|
2006-05-09 |
2011-09-27 |
Pfizer Prod Inc |
cycloalkylamino acid derivatives and their pharmaceutical compositions
|
|
NL2000613C2
(en)
|
2006-05-11 |
2007-11-20 |
Pfizer Prod Inc |
Triazole pyrazine derivatives.
|
|
CA2652442C
(en)
|
2006-05-18 |
2014-12-09 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
|
EP2065372B1
(en)
|
2006-08-28 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
|
EP2061773A4
(en)
|
2006-09-11 |
2011-01-19 |
Curis Inc |
Quinazoline based egfr inhibitors containing a zinc binding moiety
|
|
US7547781B2
(en)
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
EP1921070A1
(en)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
|
|
CN101600694A
(en)
|
2007-01-29 |
2009-12-09 |
卫材R&D管理有限公司 |
Composition for treatment of undifferentiated gastric cancer
|
|
WO2008095847A1
(en)
|
2007-02-06 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
|
|
CN101245050A
(en)
*
|
2007-02-14 |
2008-08-20 |
上海艾力斯医药科技有限公司 |
4-aniline quinazoline derivative salt
|
|
EP2851091B1
(en)
|
2007-04-13 |
2017-12-27 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer resistant to ERBB therapeutics
|
|
EP2185574B1
(en)
|
2007-09-07 |
2013-05-08 |
Agensys, Inc. |
Antibodies and related molecules that bind to 24p4c12 proteins
|
|
AU2008319366B2
(en)
|
2007-10-29 |
2012-03-01 |
Amgen Inc. |
Benzomorpholine derivatives and methods of use
|
|
MX2010004625A
(en)
|
2007-10-29 |
2010-05-20 |
Natco Pharma Ltd |
Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents.
|
|
CA2704000C
(en)
|
2007-11-09 |
2016-12-13 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
|
KR20100111291A
(en)
|
2008-02-07 |
2010-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
|
|
EA019183B1
(en)
|
2008-05-13 |
2014-01-30 |
Астразенека Аб |
Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
|
|
EP2313397B1
(en)
|
2008-08-08 |
2016-04-20 |
Boehringer Ingelheim International GmbH |
Cyclohexyloxy substituted heterocycles, medicine containing these connections, their application and production method
|
|
EP2334701A4
(en)
|
2008-10-16 |
2014-01-08 |
Univ Pittsburgh |
FULLY HUMAN ANTIBODIES DIRECTED AGAINST ANTIGEN ASSOCIATED WITH HIGH MOLECULAR WEIGHT MELANOMA AND USES THEREOF
|
|
MX2011004824A
(en)
|
2008-11-07 |
2012-01-12 |
Triact Therapeutics Inc |
USE OF CATHOLIC BUTANE DERIVATIVES IN THERAPY AGAINST CANCER.
|
|
AU2010210986A1
(en)
|
2009-02-09 |
2011-08-25 |
Supergen, Inc. |
Pyrrolopyrimidinyl Axl kinase inhibitors
|
|
JP2012518657A
(en)
|
2009-02-25 |
2012-08-16 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
Combined anticancer treatment
|
|
WO2010099137A2
(en)
|
2009-02-26 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the emt status of tumor cells in vivo
|
|
WO2010099364A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
JP2012519281A
(en)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
Methods for identifying mesenchymal tumor cells or agents that inhibit their production
|
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
|
WO2010107968A1
(en)
|
2009-03-18 |
2010-09-23 |
Osi Pharmaceuticals, Inc. |
Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
|
|
CA2772194A1
(en)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Benzimidazole derivatives
|
|
WO2011058164A1
(en)
|
2009-11-13 |
2011-05-19 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
MX343383B
(en)
|
2010-02-12 |
2016-11-03 |
Pfizer Inc * |
Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl }-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one.
|
|
US20110275644A1
(en)
|
2010-03-03 |
2011-11-10 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
CA2783665A1
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
ES2695899T3
(en)
|
2010-06-16 |
2019-01-11 |
Univ Pittsburgh Commonwealth Sys Higher Education |
Antibodies against endoplasmin and its use
|
|
BR112012032462A2
(en)
|
2010-06-25 |
2016-11-08 |
Eisai R&D Man Co Ltd |
antitumor agent employing compounds which, in combination, have kinase inhibiting effect.
|
|
US9056865B2
(en)
|
2010-10-20 |
2015-06-16 |
Pfizer Inc. |
Pyridine-2-derivatives as smoothened receptor modulators
|
|
US20130225524A1
(en)
*
|
2010-11-05 |
2013-08-29 |
Deping Chai |
Chemical Compounds
|
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
|
MX2013010330A
(en)
|
2011-03-09 |
2014-11-26 |
Richard G Pestell |
Prostate cancer cell lines, gene signatures and uses thereof.
|
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
|
US8962650B2
(en)
|
2011-04-18 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
|
EP2699598B1
(en)
|
2011-04-19 |
2019-03-06 |
Pfizer Inc |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
JP6038128B2
(en)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
A biomarker for predicting and evaluating the reactivity of thyroid and renal cancer subjects to lenvatinib compounds
|
|
US9416132B2
(en)
|
2011-07-21 |
2016-08-16 |
Tolero Pharmaceuticals, Inc. |
Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
|
|
JP6297490B2
(en)
|
2011-08-31 |
2018-03-20 |
ジェネンテック， インコーポレイテッド |
Diagnostic marker
|
|
CN103814030A
(en)
|
2011-09-22 |
2014-05-21 |
辉瑞大药厂 |
Pyrrolopyrimidine and purine derivatives
|
|
CA2849120A1
(en)
|
2011-09-30 |
2013-04-18 |
Genentech, Inc. |
Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
|
|
ES2654160T3
(en)
|
2011-10-04 |
2018-02-12 |
Igem Therapeutics Limited |
Anti-HMW-MAA IgE antibodies
|
|
CN104271599A
(en)
|
2011-11-08 |
2015-01-07 |
辉瑞公司 |
Methods of treating inflammatory diseases using anti-M-CSF antibodies
|
|
WO2013096153A1
(en)
*
|
2011-12-22 |
2013-06-27 |
Glaxosmithkline Llc |
Chemical compounds
|
|
WO2013096151A1
(en)
*
|
2011-12-22 |
2013-06-27 |
Glaxosmithkline Llc |
Chemical compounds
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
AU2013262977A1
(en)
|
2012-05-14 |
2015-01-22 |
Prostagene, Llc |
Using modulators of CCR5 for treating cancer
|
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
|
ES2644758T3
(en)
|
2012-10-16 |
2017-11-30 |
Tolero Pharmaceuticals, Inc. |
PKM2 modulators and methods for use
|
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
|
BR112015009004A8
(en)
|
2012-12-21 |
2021-07-20 |
Eisai R&D Man Co Ltd |
amorphous form of quinoline derivative and method of production thereof
|
|
US9834575B2
(en)
|
2013-02-26 |
2017-12-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
KR20210149232A
(en)
|
2013-03-14 |
2021-12-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Jak2 and alk2 inhibitors and methods for their use
|
|
US20160051556A1
(en)
|
2013-03-21 |
2016-02-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
|
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
|
CA2912219C
(en)
|
2013-05-14 |
2021-11-16 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
CA2923667A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
EP3052102B1
(en)
|
2013-10-04 |
2019-12-04 |
Aptose Biosciences Inc. |
Compositions for treating cancers
|
|
UA115388C2
(en)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
|
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
AU2015254943B2
(en)
|
2014-04-30 |
2019-04-04 |
Pfizer Inc. |
Cycloalkyl-linked diheterocycle derivatives
|
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
|
EP3177320B1
(en)
|
2014-07-31 |
2021-01-06 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Human monoclonal antibodies against epha4 and their use
|
|
JO3783B1
(en)
|
2014-08-28 |
2021-01-31 |
Eisai R&D Man Co Ltd |
High purity quinoline derivative and method for its production
|
|
WO2016097918A1
(en)
|
2014-12-18 |
2016-06-23 |
Pfizer Inc. |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
|
MY188938A
(en)
|
2014-12-24 |
2022-01-13 |
Genentech Inc |
Therapeutic, diagnostic and prognostic methods for cancer of the bladder
|
|
BR112017017428A2
(en)
|
2015-02-25 |
2018-04-03 |
Eisai R&D Management Co., Ltd. |
A bitter taste inhibition method of a quinoline derivative
|
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
|
BR112017022666A8
(en)
|
2015-04-20 |
2022-10-18 |
Tolero Pharmaceuticals Inc |
PREPARING RESPONSE TO ALVOCIDIB BY MITOCHONDRIAL PROFILING
|
|
EP3288957A4
(en)
|
2015-05-01 |
2019-01-23 |
Cocrystal Pharma, Inc. |
NUCLEOSIDE ANALOGUES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE AND CANCER FAMILY VIRUS INFECTIONS
|
|
CN107849073B
(en)
|
2015-05-18 |
2020-04-03 |
特雷罗药物股份有限公司 |
Avocidide prodrugs with increased bioavailability
|
|
KR102705821B1
(en)
|
2015-06-16 |
2024-09-12 |
가부시키가이샤 프리즘 바이오랩 |
Anticancer drug
|
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
|
CA2993659A1
(en)
|
2015-08-03 |
2017-02-09 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
|
SG11201801083UA
(en)
|
2015-08-20 |
2018-03-28 |
Eisai R&D Man Co Ltd |
Tumor therapeutic agent
|
|
MX2018006781A
(en)
|
2015-12-03 |
2018-11-09 |
Agios Pharmaceuticals Inc |
Mat2a inhibitors for treating mtap null cancer.
|
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
CN110234659A
(en)
|
2016-12-19 |
2019-09-13 |
特雷罗药物股份有限公司 |
Analytical peptide and method for sensitivity analysis
|
|
CN116606261A
(en)
|
2016-12-22 |
2023-08-18 |
美国安进公司 |
KRAS G12C inhibitors and methods of use thereof
|
|
BR112019014127A2
(en)
|
2017-02-08 |
2020-02-11 |
Eisai R&D Management Co., Ltd. |
PHARMACEUTICAL COMPOSITION FOR TUMOR TREATMENT
|
|
WO2018212202A1
(en)
|
2017-05-16 |
2018-11-22 |
Eisai R&D Management Co., Ltd. |
Treatment of hepatocellular carcinoma
|
|
JOP20190272A1
(en)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
|
CA3075046A1
(en)
|
2017-09-08 |
2019-03-14 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
|
JP7196160B2
(en)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib
|
|
US20200237766A1
(en)
|
2017-10-13 |
2020-07-30 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
|
MX2020010836A
(en)
|
2018-05-04 |
2021-01-08 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same.
|
|
AU2019262599B2
(en)
|
2018-05-04 |
2023-10-12 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
MA52564A
(en)
|
2018-05-10 |
2021-03-17 |
Amgen Inc |
KRAS G12C INHIBITORS FOR CANCER TREATMENT
|
|
MX2020012731A
(en)
|
2018-06-01 |
2021-02-22 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same.
|
|
WO2019241157A1
(en)
|
2018-06-11 |
2019-12-19 |
Amgen Inc. |
Kras g12c inhibitors for treating cancer
|
|
JP7369719B2
(en)
|
2018-06-12 |
2023-10-26 |
アムジエン・インコーポレーテツド |
KRas G12C inhibitors and methods of using the same
|
|
AU2019310590A1
(en)
|
2018-07-26 |
2021-01-14 |
Sumitomo Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
|
AU2019352741A1
(en)
|
2018-10-04 |
2021-05-06 |
Assistance Publique-Hôpitaux De Paris (Aphp) |
EGFR inhibitors for treating keratodermas
|
|
JP7516029B2
(en)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Improved synthesis of key intermediates for KRAS G12C inhibitor compounds
|
|
WO2020106640A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
JP7377679B2
(en)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
|
|
CA3119807A1
(en)
|
2018-12-04 |
2020-06-11 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
|
AU2019403488B2
(en)
|
2018-12-20 |
2025-07-24 |
Amgen Inc. |
KIF18A inhibitors
|
|
CN120398830A
(en)
|
2018-12-20 |
2025-08-01 |
美国安进公司 |
KIF18A inhibitors
|
|
MA54546A
(en)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS
|
|
WO2020132653A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
|
CN113412262A
(en)
|
2019-02-12 |
2021-09-17 |
大日本住友制药肿瘤公司 |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
KR20210146287A
(en)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
Bicyclic heteroaryl compounds and uses thereof
|
|
US20230096028A1
(en)
|
2019-03-01 |
2023-03-30 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
|
CN113747895A
(en)
|
2019-03-22 |
2021-12-03 |
大日本住友制药肿瘤公司 |
Compositions comprising PKM2 modulators and methods of treatment therewith
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
UA129871C2
(en)
|
2019-05-21 |
2025-08-27 |
Емджен Інк. |
SOLID FORMS
|
|
US20220289724A1
(en)
|
2019-08-02 |
2022-09-15 |
Amgen Inc. |
Kif18a inhibitors
|
|
CN114401953A
(en)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
KIF18A inhibitors
|
|
CA3147451A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
EP4007638A1
(en)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Pyridine derivatives as kif18a inhibitors
|
|
CA3155857A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER
|
|
JP2022553859A
(en)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
RAS inhibitor
|
|
CR20220240A
(en)
|
2019-11-04 |
2022-08-03 |
Revolution Medicines Inc |
RAS INHIBITORS
|
|
CA3159561A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
PH12022551102A1
(en)
|
2019-11-08 |
2023-11-20 |
Revolution Medicines Inc |
Bicyclic heteroaryl compounds and uses thereof
|
|
AU2020383535A1
(en)
|
2019-11-14 |
2022-05-05 |
Amgen Inc. |
Improved synthesis of KRAS G12C inhibitor compound
|
|
EP4058453A1
(en)
|
2019-11-14 |
2022-09-21 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
|
CN114980976A
(en)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
Covalent RAS inhibitors and uses thereof
|
|
CN114929279A
(en)
|
2020-01-07 |
2022-08-19 |
锐新医药公司 |
Methods of administering SHP2 inhibitors and treating cancer
|
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
|
|
CN116209438A
(en)
|
2020-09-03 |
2023-06-02 |
锐新医药公司 |
Treatment of malignant diseases with SHP2 mutations using SOS1 inhibitors
|
|
CN116457358A
(en)
|
2020-09-15 |
2023-07-18 |
锐新医药公司 |
Indole derivatives as RAS inhibitors for the treatment of cancer
|
|
WO2023077259A1
(en)
*
|
2021-11-02 |
2023-05-11 |
Enliven Therapeutics, Inc. |
Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
|
|
CN117396472A
(en)
|
2020-12-22 |
2024-01-12 |
上海齐鲁锐格医药研发有限公司 |
SOS1 inhibitors and uses thereof
|
|
CN117500811A
(en)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
Covalent RAS inhibitors and uses thereof
|
|
WO2022235870A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
|
AR125782A1
(en)
|
2021-05-05 |
2023-08-16 |
Revolution Medicines Inc |
RAS INHIBITORS
|
|
AR127308A1
(en)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
RAS INHIBITORS
|
|
WO2023081637A1
(en)
|
2021-11-02 |
2023-05-11 |
Enliven Therapeutics, Inc. |
Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
|
|
JP2025500878A
(en)
|
2021-12-17 |
2025-01-15 |
ジェンザイム・コーポレーション |
PYRAZOLO-PYRAZINE COMPOUNDS AS SHP2 INHIBITORS
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
CN119136806A
(en)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
Methods for treating immune-refractory lung cancer
|
|
KR20250022133A
(en)
|
2022-06-10 |
2025-02-14 |
레볼루션 메디슨즈, 인크. |
macrocyclic RAS inhibitors
|
|
PE20251879A1
(en)
|
2022-10-14 |
2025-07-22 |
Black Diamond Therapeutics Inc |
Cancer treatment methods using isoquinoline or 6-azaquinoline derivatives
|
|
TW202504611A
(en)
|
2023-03-30 |
2025-02-01 |
美商銳新醫藥公司 |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
WO2024211663A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
WO2024216016A1
(en)
|
2023-04-14 |
2024-10-17 |
Revolution Medicines, Inc. |
Crystalline forms of a ras inhibitor
|
|
WO2024216048A1
(en)
|
2023-04-14 |
2024-10-17 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
TW202508595A
(en)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
Combination therapy for a ras related disease or disorder
|
|
WO2025034702A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Rmc-6291 for use in the treatment of ras protein-related disease or disorder
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025137507A1
(en)
|
2023-12-22 |
2025-06-26 |
Regor Pharmaceuticals, Inc. |
Sos1 inhibitors and uses thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|